Vaccination turnout for people aged 25-44: 66% vaccinated at least once The 26th RIVM vaccination update now shows vaccination turnout for people aged 25-44 years by municipality. This involves people who have received at least one COVID-19 vaccination.
More attention needs to be paid to the safe recycling of waste According to the National Institute for Public Health and the Environment (RIVM) there needs to be a greater (international) focus on, and increased awareness of, the safe recycling of waste.
Heterologous vaccination from 16 July on Following an advisory report by the Health Council, Minister De Jonge decided on 6 July 2021, effective as of 16 July, that people who had received one vaccination with AstraZeneca could opt for the Pfizer/BioNTech for their second jab.
Vaccination coverage is rising, while data is increasingly comprehensive The RIVM vaccination update this week has been expanded to include vaccination coverage by municipality, specifying full COVID-19 vaccination among people aged 65 and over and people aged 45-64 years.
Long COVID also possible after a mild case: interim research results More than 95% of the 1,741 participants in RIVM’s LongCOVID study, who reported long-term symptoms after COVID-19, had mild symptoms during the acute phase of the infection.
Antimicrobial resistance in the Netherlands stable in 2020 In 2020, the year of the coronavirus SARS-CoV-2 pandemic, resistant bacteria were not found more often in patients in the Netherlands than before the outbreak.
At least 87% of people over 65 vaccinated at least once: high turnout, few regional differences Four months after the launch of the vaccination campaign, at least 87% of people over 65 in the Netherlands have been vaccinated against COVID-19 at least once.
Quality assessment of SARS-CoV-2 antigen test diagnostics: good performance at public test sites in the Netherlands In their role as WHO reference laboratories, RIVM and Erasmus UMC conducted a study on the quality of SARS-CoV-2 antigen diagnostics in the Netherlands.
Long-term symptoms more common after Lyme disease More than a quarter of people with Lyme disease continue to have long-term symptoms that lead to limitations in daily life even after treatment.
RIVM updates guidelines for AstraZeneca interval As of 21 May, RIVM updated the guidelines for the interval between two doses of the AstraZeneca vaccine. The interval can now be between 6 and 14 weeks.